SEC Form 4 · accession 0001562180-17-003065
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gil J Van Lunsen
Director
Period of report
Sep 29, 2017
Accepted (ET)
Sep 29, 2017 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 29, 2017 | M | 45,000 | $10.58 | A | 55,260 | D | |
| Common StockF2 | Sep 29, 2017 | S | 39,928 | $12.36 | D | 15,332 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F3 | $10.58 | Sep 29, 2017 | M | 45,000 | D | Nov 1, 2010 | Nov 1, 2017 | Common Stock | 45,000 | 0 | D |
Explanation of responses
- F1This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price.
- F2The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.
- F3The option vested in 3 equal annual installments beginning on November 1, 2008.